El trasplante alogénico de progenitores hematopoyéticos es una opción potencialmente curativa para numerosos pacientes con hemopatías malignas debido principalmente al régimen de acondicionamiento y al efecto injerto contra leucemia/tumor (EICL) mediado por las células inmunes del donante. Sin embargo, la enfermedad injerto contra receptor...
-
June 29, 2018 (v1)PublicationUploaded on: March 27, 2023
-
February 8, 2024 (v1)Publication
This multicenter phase I trial was designed to evaluate the safety and efficacy of bortezomib (Bz) as part of both the conditioning regimen and the graft-versus-host disease (GvHD) prophylaxis. Patients received fludarabine, melphalan and Bz (days -9 and -2). GVHD prophylaxis consisted of Bz (days +1, +4, and +7), sirolimus (Siro) from day -5...
Uploaded on: February 11, 2024 -
February 9, 2022 (v1)Publication
Frequency of additional chromosomal abnormalities in chronic myeloid leukemia (CML) is estimated to be 7% in chronic phase and increases to 40–70% in advanced disease. Progression of CML from chronic phase to accelerated phase or blast crisis is often associated with secondary chromosomal aberrations. We report an exceptional case of CML as...
Uploaded on: December 4, 2022